---
title: "CRO concept stocks perform actively, Medicilon rises nearly 18%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248905016.md"
description: "On July 17th, CRO concept stocks performed actively. As of 14:26, Medicilon rose nearly 18%, HitGen had previously hit the limit up, HITECK and BOJI CRO rose over 10%, while ChemPartner, Sun-Novo, and Hongbo Pharmaceutical rose over 5%"
datetime: "2025-07-17T06:29:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248905016.md)
  - [en](https://longbridge.com/en/news/248905016.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248905016.md)
---

# CRO concept stocks perform actively, Medicilon rises nearly 18%

On July 17th, CRO concept stocks performed actively. As of 14:26, Medicilon rose nearly 18%, HitGen had previously hit the limit up, HITECK and BOJI CRO rose over 10%, ChemPartner, Sun-Novo, and Hongbo Pharmaceutical rose over 5%

### Related Stocks

- [688202.CN](https://longbridge.com/en/quote/688202.CN.md)
- [688222.CN](https://longbridge.com/en/quote/688222.CN.md)
- [300683.CN](https://longbridge.com/en/quote/300683.CN.md)
- [300404.CN](https://longbridge.com/en/quote/300404.CN.md)
- [300149.CN](https://longbridge.com/en/quote/300149.CN.md)
- [688621.CN](https://longbridge.com/en/quote/688621.CN.md)

## Related News & Research

- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [Orion Pharma to reveal initial results from Phase 1/2 TEADES study of ODM-212 at 2026 ASCO® Meeting.](https://longbridge.com/en/news/287177935.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [<![CDATA[Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs]]>](https://longbridge.com/en/news/286948461.md)